Delivery Order SPE2DR25D2006-SPE2DR26F57DN
Award Date 1/7/26
Potential Completion Date 1/8/26
Potential Value $94K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $8,424.80 by the Defense Logistics Agency for HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 22, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $53,766.20 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 ml syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $15,164.64 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of HEPLISAV-B hepatitis B vaccine (20 mcg/0.5 ml syringes) with a ceiling value of $7,661.90. This is a firm fixed price delivery order with an ultimate completion date of September 15, 2025, and no set-aside designation was used in the competitive award process. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,057.16 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on October 15, 2025, with completion scheduled for October 16, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract covers the supply of HEPLISAV-B, a recombinant hepatitis B vaccine, which...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,129.05 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on January 5, 2026, with completion scheduled for January 6, 2026. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery transaction for the hepatitis B vaccine product. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,948.68 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a procurement of hepatitis B vaccine supplies to support federal medical requirements. The order is being fulfilled from AmerisourceBergen's place of performance in...
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, has been awarded a $78,864.00 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceuticals. This delivery order does not have a set-aside designation and is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $6,309.12 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a period of performance through November 4, 2024. This contract is a child task order under AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...